Edwards and DexCom CE mark blood glucose monitor
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences and DexCom have CE marked an automatic glucose monitoring system for sale in Europe. The system co-developed by the two Californian firms can now be used for automatic monitoring of blood glucose concentration in critically ill adults in hospitals. It performs multiple automatic readings each hour to predict trends, enabling efficient glycaemic control. Market evaluations of a first-generation product are expected to begin in a limited number of European sites before the end of the year, Edwards and DexCom said.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.